Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000950170-25-046213
Filing Date
2025-03-27
Accepted
2025-03-27 17:40:52
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 9720
2 EX-99.J ck0001669811-ex99_j.pdf EX-99.J 189008
  Complete submission text file 0000950170-25-046213.txt   272243
Mailing Address 6836 BEE CAVE ROAD BUILDING 3, SUITE 201 AUSTIN TX 78746
Business Address 6836 BEE CAVE ROAD BUILDING 3, SUITE 201 AUSTIN TX 78746 51285113796
Savara Inc (Subject) CIK: 0001160308 (see all company filings)

EIN.: 841318182 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-78541 | Film No.: 25780770
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 200 CLARENDON STREET BOSTON MA 02116
Business Address 200 CLARENDON STREET BOSTON MA 02116 6175162000
Bain Capital Life Sciences Fund II, L.P. (Filed by) CIK: 0001773187 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A